PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This is an open-label,single center,non-randomized,single arm exploratory study. The
objective of this study is to evaluate the efficacy and safety of PD-1 antibody plus GEMOX as
postoperative adjuvant therapy in perihilar cholangiocarcinoma with positively metastatic
lymph nodes.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University